1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. MediPharm Labs Corp.
  6. Summary
    LABS   CA58504D1006

MEDIPHARM LABS CORP.

(LABS)
  Report
Delayed Toronto Stock Exchange  -  11:02 2022-08-16 am EDT
0.0850 CAD   -5.56%
08/15MediPharm Labs Narrows Q2 Loss While Revenue Declines
MT
08/15MediPharm Labs to Seek M&A
CI
08/15TRANSCRIPT : MediPharm Labs Corp., Q2 2022 Earnings Call, Aug 15, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
08/10/2022 08/11/2022 08/12/2022 08/15/2022 08/16/2022 Date
0.09(c) 0.095(c) 0.1(c) 0.09(c) 0.085 Last
249 430 423 028 100 804 710 654 133 675 Volume
0.00% +5.56% +5.26% -10.00% -5.56% Change
More quotes
Estimated financial data (e)
Sales 2022 19,6 M 15,2 M 15,2 M
Net income 2022 -27,9 M -21,6 M -21,6 M
Net Debt 2022 - - -
P/E ratio 2022 -1,04x
Yield 2022 -
Sales 2023 28,6 M 22,2 M 22,2 M
Net income 2023 -16,2 M -12,5 M -12,5 M
Net Debt 2023 - - -
P/E ratio 2023 -1,80x
Yield 2023 -
Capitalization 24,9 M 19,3 M 19,3 M
Capi. / Sales 2022 1,27x
Capi. / Sales 2023 0,87x
Nbr of Employees 190
Free-Float 96,0%
More Financials
Company
MediPharm Labs Corp. is a Canada-based pharmaceutical company that is specialized in cannabis. The Company produces purified, pharmaceutical-like cannabis extracts and related derivative products. The Company formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Ratings of MediPharm Labs Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about MEDIPHARM LABS CORP.
08/15MediPharm Labs Narrows Q2 Loss While Revenue Declines
MT
08/15MediPharm Labs to Seek M&A
CI
08/15TRANSCRIPT : MediPharm Labs Corp., Q2 2022 Earnings Call, Aug 15, 2022
CI
08/15EARNINGS FLASH (FRANKFURT : MLZ) MEDIPHARM LABS Reports Q2 Revenue $4.362 Million
MT
08/15MediPharm Labs Corp. Reports Earnings Results for the Second Quarter and Six Months End..
CI
08/15MediPharm Labs Reports Second Quarter Results
AQ
08/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
08/11MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results
AQ
08/09MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC
AQ
08/09MediPharm Labs Corp Enters Cannabis Research Agreement with Keck School of Medicine of ..
CI
07/27MediPharm Labs Awarded $9.8 Million After Winning Lawsuit
MT
07/27MediPharm Labs Awarded Payment of $9.8M in Connection to a 2020 Statement of Claim Agai..
AQ
07/11MediPharm Labs Gains 8% as Agrees to Sell Australian Facility for At Least $6.2 Million
MT
07/11MediPharm Labs Agrees to Sell Australian Facility for At Least $6.2 Million
MT
07/11MEDIPHARM LABS BRIEF : Enters into C$6.2 Million Purchase Agreement for the Sale of Austra..
MT
More news
News in other languages on MEDIPHARM LABS CORP.
08/15MediPharm Labs réduit sa perte au deuxième trimestre, alors que ses revenus diminuent
08/15MediPharm Labs cherche à réaliser une fusion-acquisition
08/15EARNINGS FLASH (FRANKFURT : MLZ) MEDIPHARM LABS annonce un chiffre d'affaires de 4,362 mil..
08/15MediPharm Labs Corp. annonce ses résultats pour le deuxième trimestre et le semestre te..
08/09MediPharm Labs Corp conclut un accord de recherche sur le cannabis avec la Keck School ..
More news
Chart MEDIPHARM LABS CORP.
Duration : Period :
MediPharm Labs Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIPHARM LABS CORP.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 0,09 CAD
Average target price 0,13 CAD
Spread / Average Target 48,1%
EPS Revisions
Managers and Directors
David A. Pidduck Chief Executive Officer & Director
Keith Strachan President
Greg Hunter Chief Financial Officer
Chris Taves Chairman
Ina Shira Dubinsky Lead Scientist-Secondary Processing